Newsroom
July 31, 2024
Scientists from The University of Texas Health Science Center at San Antonio, also known as UT Health San Antonio, led a pilot study of the Food and Drug Administration-approved antiretroviral drug lamivudine, to determine if it could be a potential treatment for Alzheimer’s disease. Almost half of what makes up the human genome are […]
July 15, 2024
Sudha Seshadri, MD, Department of Neurology, director of the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, was interviewed for this article. Read More
July 12, 2024
Sudha Seshadri, MD, Department of Neurology, director of the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, was mentioned in this article. Read More
June 21, 2024
Study led partly by UT Health San Antonio suggests new prevention strategies Research led in part by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) finds that the most common cerebral small-vessel disease feature seen in brain magnetic resonance imaging is a primary vascular factor associated with dementia risk. […]
March 18, 2024
Significant levels of amyloid beta plaques and tau tangles in the brain are classic hallmarks of Alzheimer’s disease. These precursors are also prevalent in the understudied population of those with Down syndrome.
March 1, 2024
Margaret Flanagan, MD, associate professor/clinical in the Department of Pathology and Laboratory Medicine in the Joe R. and Teresa Lozano Long School of Medicine at the University of Texas Health Science Center at San Antonio (UT Health San Antonio) received a Rising STARs (Science and Technology Acquisition and Retention) $100,000 award from The University of […]